AQP4 and neuromyelitis optica: A two-year clinical trial was conducted on 81 NMO patients (seropositive or seronegative for AQP4-IgG), where approximately half were administered satralizumab (IL-6 receptor blocking antibody) and half were kept on placebo, in addition to stable immunosuppressive therapy.